西尔图因激活剂和抑制剂发展的当前趋势
Karina L Bursch1,2, Christopher J Goetz1, Brian C Smith1,2,3
1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Molecules (Basel, Switzerland)
|March 13, 2024
概括
作为关键的代谢调节剂,Sirtuins可以具有保护性或有害的作用. 本综述强调了Sirtuin研究和治疗开发的关键激活剂和抑制剂.
科学领域:
- 生物化学和分子生物学
- 代谢和衰老研究 研究
背景情况:
- 赛尔图因 (NAD+依赖性脱乙酶) 是重要的代谢调节剂,影响细胞过程.
- 人类的sirtuins (Sirt1-7) 具有多种作用,与延长寿命和与衰老相关的疾病有关.
研究的目的:
- 审查特征良好的Sirtuin激活剂和抑制剂.
- 引导研究人员选择强效和选择性调制剂,以研究素在健康和疾病中的作用.
主要方法:
- 对现有的Sirtuin激活剂和抑制剂的文献综述.
- 专注于具有被证明的选择性,功效和细胞活性的化合物.
主要成果:
- 鉴定具有治疗潜力的关键素激活剂和抑制剂.
- 讨论Sirtuins在细胞功能中的双重作用.
结论:
- 赛尔图因调节器对了解赛尔图因生物学和开发新疗法具有前景.
- 提供了为选择最佳的sirtuin调节器进行研究的建议.
相关概念视频
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Co-activators and Co-repressors
7.4K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.4K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


